Although virtually no one in the urban bubble where biopharmaceutical companies reside expected it to happen, Donald Trump won. So, now what?
Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.
Biogen reported Q2 profit that blew past Wall Street estimates; Chief Executive George Scangos will step down in the coming months once a successor is found.
Abbott Laboratories reported better-than-expected quarterly sales and profit with strong sales in its medical device business.
Bristol-Myers Squibb Co said the U.S. Food and Drug Administration had approved the expanded use of its cancer drug, Opdivo, to treat an additional form of advanced skin cancer. Opdivo, […]
November 24, 2015By Mark Terry, BioSpace.com Breaking News Staff Now that the Pfizer (PFE)-Allergan (AGN) merger is official, the company and analysts are looking at details about the merged […]
November 17, 2015By Mark Terry, BioSpace.com Breaking News Staff Boston-based Vertex Pharmaceuticals (VRTX) presents an unusual business model one that has been the focus of a Harvard case study. […]
AbbVie Inc (ABBV.N) reported higher quarterly sales and net income on Friday and forecast double-digit growth of earnings per share through 2020, putting the drugmaker in line to beat Wall […]
Amgen Inc (AMGN.O) on Wednesday reported much higher-than-expected third-quarter profit, helped by a 30-percent spike in revenue from the rheumatoid arthritis drug Enbrel due to price increases and inventory stocking. […]
FDA approves Amgen’s injected immunotherapy for melanomaAnalysts, Approvals, Biologics License Application (BLA), Biotech, Biotechnology, Clinical Trials, FDA, FDA/Regulatory, Forecasts, Health, Herpes, Herpes Simplex Virus, Immune System, Immune Systems, Immunotherapies, Immunotherapy, Melanoma, Melanoma Lesions, Pricing, R&D, Shares, Shares, Studies, Viral Therapy, Wall Street, Warning Labeling
U.S. health regulators on Tuesday approved Amgen Inc’s novel cancer immunotherapy for injection into melanoma lesions and lymph nodes of patients with the deadliest form of skin cancer that returns […]